Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Solifenacin in overactive bladder syndrome.

Dene Simpson1, Antona J Wagstaff

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|December 21, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-dose doxepin: in the treatment of insomnia.

CNS drugs·2010
Same author

Tenofovir disoproxil fumarate: in chronic hepatitis B.

Drugs·2009
Same author

Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2009
Same author

Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.

Drugs·2009
Same author

Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser.

Drugs·2009
Same author

Spotlight on fondaparinux sodium in acute coronary syndromes.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2008

Solifenacin effectively treats overactive bladder (OAB) symptoms like urgency and incontinence. This bladder-selective medication improved quality of life and was well-tolerated in clinical trials.

Area of Science:

  • Pharmacology
  • Urology
  • Clinical Trials

Background:

  • Solifenacin is a muscarinic receptor antagonist with demonstrated bladder selectivity in animal models.
  • Existing treatments for overactive bladder (OAB) have varying efficacy and side effect profiles.

Purpose of the Study:

  • To evaluate the efficacy and safety of solifenacin in treating symptoms of overactive bladder (OAB).
  • To compare solifenacin's effectiveness against placebo and tolterodine extended release (ER).

Main Methods:

  • Large, 12-week, randomized, double-blind, multicenter clinical trials.
  • Assessment of OAB symptoms (urgency, frequency, incontinence, nocturia) and functional bladder capacity.
  • Comparison of solifenacin (5 and 10mg once daily) with placebo and tolterodine ER (4mg daily).

Related Experiment Videos

Main Results:

  • Solifenacin significantly improved OAB symptoms and increased bladder capacity compared to placebo.
  • Solifenacin demonstrated non-inferiority to tolterodine ER for urinary frequency and superior efficacy for other OAB symptoms.
  • Over half of incontinent patients became continent with solifenacin treatment.
  • Health-related quality of life significantly improved with solifenacin and was maintained during extension studies.

Conclusions:

  • Solifenacin is an effective treatment for OAB, offering significant symptom improvement and enhanced quality of life.
  • Solifenacin shows comparable or superior efficacy to tolterodine ER for OAB symptoms.
  • The drug was generally well-tolerated, with dry mouth, constipation, and blurred vision being the most common adverse events.